Feasibility of psychosocial interventions for preventing blood borne virus infection in people who inject drugs

Feasibility of psychosocial interventions for preventing blood borne virus infection in people who inject drugs: a feasibility randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN66453696

Enrollment

128

Registered

2014-09-24

Start date

2015-10-01

Completion date

Unknown

Last updated

2018-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood borne viruses among people who inject drugs Infections and Infestations

Interventions

All participants in the feasibility trial will receive treatment as usual in addition to the trial interventions. In community addiction treatment, treatment as usual in NHS/ 3rd sector Community Add

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. PWID are aged 18 and older attending NHS and third sector community addiction and harm reduction clinics and needle exchange programmes (static and mobile) 2. Who have injected drugs at least once in the past 4 weeks 3. Who plan to stay in the area for the next 3 months 4. Who are able to complete the assessment (alone or with help of researcher) and communicate in a group intervention in English. PWID are not routinely screened for BBV at drug treatment services & therefore do not always know their BBV status. As the focus of the proposed psychosocial intervention will be to increase knowledge about transmission/ reinfection & promote motivation/skills for safer injecting & sex practices, the intervention content will be the same regardless of BBV status.

Exclusion criteria

Exclusion criteria: PWID who are too intoxicated or in withdrawal to give informed consent.

Design outcomes

Primary

Measure	Time frame
The proposed study will examine feasibility and is not powered to determine effect. Differences in number of risk events in past month will be assessed pre, end and 1 month post intervention using intention-to-treat analysis. The Blood Borne Virus Transmission Risk Assessment Questionnaire (TRAQ) will assess the frequency with which PWID have participated in specific injecting, sexual and other risk-practices in the previous month that may expose them to blood-borne viruses. The REDUCE questionnaire on Hepatitis C transmission knowledge and The brief HIV-Knowledge Questionnaire will measure transmission knowledge.	—

Measure

Time frame

The proposed study will examine feasibility and is not powered to determine effect. Differences in number of risk events in past month will be assessed pre, end and 1 month post intervention using intention-to-treat analysis. The Blood Borne Virus Transmission Risk Assessment Questionnaire (TRAQ) will assess the frequency with which PWID have participated in specific injecting, sexual and other risk-practices in the previous month that may expose them to blood-borne viruses. The REDUCE questionnaire on Hepatitis C transmission knowledge and The brief HIV-Knowledge Questionnaire will measure transmission knowledge.

—

Secondary

Measure	Time frame
Quality of life will be measured using EQ-5D	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 8, 2026